Anti-amyloid antibodies represent the first generation of disease-modifying treatments for Alzheimer's disease. After decades of failed amyloid-targeting trials, lecanemab (Leqembi) received traditional FDA approval in 2023 and donanemab (Kisunla) in 2024 — both based on randomized trials showing slowed cognitive decline. The therapeutic landscape is shifting, with substantial uncertainty about real-world impact.
Mechanism: these are monoclonal antibodies that bind beta-amyloid in specific forms (lecanemab binds soluble protofibrils, donanemab binds aggregated plaques). Bound amyloid is cleared from the brain. PET imaging confirms substantial plaque reduction over months of treatment.
Clinical benefit is real but modest. Lecanemab slowed cognitive decline by approximately 27% over 18 months on CDR-SB scale; donanemab approximately 35%. Effects on patient-relevant outcomes (function, caregiver burden, time to nursing home) are less clear and less measured. Critics argue the magnitude is small relative to costs and risks; advocates argue any meaningful slowing of progression matters.
ARIA — Amyloid-Related Imaging Abnormalities — is the major safety concern. Two forms:
ARIA-E (edema/effusion) — cerebral edema, typically asymptomatic but can produce headache, confusion, seizures, focal neurologic deficits in severe cases.
ARIA-H (hemorrhage) — microhemorrhages or larger hemorrhages.
Incidence: 15-30% of treated patients depending on agent and population. APOE4 carriers, particularly homozygotes, have substantially higher risk and require careful counseling. Most ARIA is asymptomatic and detected on monitoring MRI; rare cases are severe or fatal.
Required MRI monitoring during treatment: before doses 5, 7, 14 with lecanemab; on similar schedules with donanemab. Detection of ARIA may require holding doses or discontinuation. Practical implications: substantial infrastructure required for safe administration.
Candidate selection:
Required: confirmed Alzheimer's pathology (amyloid PET or CSF biomarkers — not just clinical diagnosis), MCI due to AD or mild AD dementia (not moderate-severe).
Cautions: anticoagulation (relative contraindication — bleeding risk), prior intracerebral hemorrhage, certain microhemorrhage burden on baseline MRI, APOE4 homozygosity (informed consent essential).
Excluded: moderate-to-severe AD, patients without confirmed amyloid pathology, those unable to undergo regular MRI monitoring, those with significant cerebrovascular disease.
Cost is substantial — list prices around $26,000/year, plus infusion administration, MRI monitoring, biomarker testing. Coverage variable. Real-world access constrained.
The ongoing debate: some argue these treatments represent meaningful progress in a previously stagnant therapeutic landscape — slowing the disease, however modestly, matters when there is otherwise nothing. Others argue the clinical benefit is too small, the costs (financial, time, ARIA risk) too large, and that resources might be better spent on care quality improvements that benefit many more patients.
When you encounter an early Alzheimer's patient potentially appropriate for anti-amyloid therapy, the conversation requires nuance — explain the modest benefit, the ARIA risks, the monitoring burden, the cost, the alternative of conventional management. Reasonable patients with reasonable clinicians come to different decisions. The therapeutic landscape will continue to evolve.